Marker Therapeutics (NASDAQ:MRKR) shareholders are up 20% this past week, but still in the red over the last five years

Marker Therapeutics' share price has surged 45% in 3 months, but dropped 90% in 5 years. Revenue growth is vital for the company's recovery despite recent market cap gains. Investors should consider balance sheet strength and other key metrics before investing.